ligand pharmaceuticals-cl b
(LGND:NASDAQ GM)
ligand pharmaceuticals-cl b (LGND) Snapshot
|
Open
$26.88
|
Previous Close
$27.38
|
|
|
Day High
$28.43
|
Day Low
$26.31
|
|
|
52 Week High
04/23/13 - $29.92
|
52 Week Low
05/24/12 - $11.42
|
|
|
Market Cap
565.6M
|
Average Volume 10 Days
145.4K
|
|
|
EPS TTM
--
|
Shares Outstanding
20.2M
|
|
|
EX-Date
04/3/07
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
ligand pharmaceuticals-cl b (LGND) Related Businessweek News
No Related Businessweek News Foundligand pharmaceuticals-cl b (LGND) Details
Ligand Pharmaceuticals Incorporated, a biotechnology company, engages in the acquisition and development of royalty revenue generating assets in the United States. The company’s assets include PROMACTA, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Viviant/Conbriza for the treatment of postmenopausal osteoporosis; Nexterone, an injectable formulation; and Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis. Its late-stage development programs comprise PROMACTA, which is in is in Phase II clinical studies for the treatment of oncology-related thrombocytopenia in patients with solid tumors, sarcoma, and Myelodysplastic Syndrome. The company’s late-stage development programs also include Merck Captisol program that is in Phase III studies; Captisol-enabled Clopidogrel, which is in Phase III studies; RE-021 program, a dual acting receptor antagonist that is in various stages of development for indications of severe kidney diseases; Dinaciclib that is in Phase IIb/III adaptive clinical trials for the treatment of patients with refractory chronic lymphocytic leukemia; and Beta-Secretase Inhibitor, which is in Phase II/III studies for treating Alzheimer's disease. In addition, its late-stage development programs comprise Captisol-enabled Delafloxacin, a Phase III clinical trial product for the management of acute seizure disorder; and Captisol-enabled Delafloxacin that is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections. The company has alliances with GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly and Co., Spectrum Pharmaceuticals, and The Medicines Company. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.
ligand pharmaceuticals-cl b (LGND) Top Compensated Officers
ligand pharmaceuticals-cl b (LGND) Key Developments
Ligand Pharmaceuticals Incorporated reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company's total revenues were $11,651,000 compared to $5,636,000 a year ago. Gain from operations was $3,932,000 compared to loss from operations of $839,000 a year ago. Income from continuing operations was $1,304,000 or $0.06 per basic and diluted share compared to loss from continuing operations of $738,000 or $0.04 per basic and diluted share a year ago. Net income was $1,495,000 or $0.07 per basic and diluted share compared $1,133,000 or $0.06 per basic and diluted share a year ago. Non GAAP income from continuing operations was $1,841,000 or $0.09 per basic and diluted share compared to non-GAAP loss from continuing operations of $513,000 or $0.03 per basic and diluted share a year ago. Non GAAP net income was $1,841,000 or $0.09 per basic and diluted share compared to non GAAP net loss of $513,000 or $0.03 per basic and diluted share a year ago. The company reaffirmed its previous 2013 financial forecast; the company expects total revenues to be between $43 million and $46 million, and earnings per diluted share to be between $0.47 and $0.51. The company expects combined R&D and G&A expenses for the year to not exceed $27 million. For the second quarter of 2013, the company estimated revenues to be between $9.0 million and $9.5 million, and earnings per diluted share to be between $0.03 and $0.05.
Ligand Pharmaceuticals Incorporated Presents at Merrill Lynch 2013 Health Care Conference, May-15-2013 11:20 AM. Venue: Encore at Wynn, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States. Speakers: John L. Higgins, Chief Executive Officer, President and Executive Director.
Ligand Pharmaceuticals Incorporated announced that they will report Q1, 2013 results at 9:04 PM, GMT Standard Time on May 08, 2013
| Recently Viewed | |||
| LGND:US | $27.95 USD | +0.57 |  |
| Company | Last | Change |
| Biosante Pharmaceuticals Inc | $1.15 USD | +0.01 |
| Columbia Laboratories Inc | $0.62 USD | 0.00 |
| View Industry Companies | ||
Industry Analysis
LGND
Industry Average
| Valuation | LGND | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 15.0x |
|
| Price/Book | 18.3x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 14.4x |
|
Post a JobJobs
Sponsored Financial Commentaries
Sponsored Links
To contact LIGAND PHARMACEUTICALS-CL B, please visit www.ligand.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
